Compare Mesoblast Limited (MESO) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Unity Software Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Unity Software Inc trades at $30.3 (market cap $13.01B). The key difference: Unity Software Inc is far larger — about 6× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| MESO | U | |
|---|---|---|
Market Cap | $2.17B | $13.01B |
Sector | Technology | Technology |
52-Week High | $20.96 | $49.47 |
52-Week Low | $12.88 | $17.13 |
Enterprise Value | $2.17B | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Unity Software (U) trades at $30.14, up 3.97% in the last session, with a bearish technical signal despite recent momentum. Revenue held at $1.85B in 2025, but net losses narrowed to -$403M, improving margins. Analysts are bullish with a $36.50 consensus target, citing AI-driven advertising potential. Cash flow strengthened with $423M from operations in 2025, though high debt and profitability challenges persist.
The stock offers upside if AI initiatives accelerate revenue growth, but risks include sustained losses and competitive pressure. With 69% buy ratings, Wall Street sees value, yet investors must weigh execution risks against the 21% discount to target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
